Last reviewed 2026-04-23 · How we verify

Vasovist (BAY86-5283, MS-325)

Bayer · Phase 3 active Small molecule

Vasovist (BAY86-5283, MS-325) is a Contrast agent Small molecule drug developed by Bayer. It is currently in Phase 3 development for Contrast agent for MRI scans.

Vasovist is a gadolinium-based contrast agent that works by enhancing the visibility of blood vessels in magnetic resonance imaging (MRI) scans.

Vasovist is a gadolinium-based contrast agent that works by enhancing the visibility of blood vessels in magnetic resonance imaging (MRI) scans. Used for Contrast agent for MRI scans.

At a glance

Generic name	Vasovist (BAY86-5283, MS-325)
Sponsor	Bayer
Drug class	Contrast agent
Modality	Small molecule
Therapeutic area	Imaging
Phase	Phase 3

Mechanism of action

It does this by binding to the gadolinium ion, which then accumulates in the blood vessels and enhances the signal in MRI images. This allows for better visualization of the blood vessels and surrounding tissues.

Approved indications

Contrast agent for MRI scans

Common side effects

Nausea
Headache
Allergic reactions

Key clinical trials

Comparison Study of Vasovist® Magnetic Resonance Angiography (MRA) and an MRA With a Conventional Extracellular Contrast Agent With X-ray Angiography in Patients With Peripheral Artery Disease (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Vasovist (BAY86-5283, MS-325) CI brief — competitive landscape report
Vasovist (BAY86-5283, MS-325) updates RSS · CI watch RSS
Bayer portfolio CI

Frequently asked questions about Vasovist (BAY86-5283, MS-325)

What is Vasovist (BAY86-5283, MS-325)?

Vasovist (BAY86-5283, MS-325) is a Contrast agent drug developed by Bayer, indicated for Contrast agent for MRI scans.

How does Vasovist (BAY86-5283, MS-325) work?

Vasovist is a gadolinium-based contrast agent that works by enhancing the visibility of blood vessels in magnetic resonance imaging (MRI) scans.

What is Vasovist (BAY86-5283, MS-325) used for?

Vasovist (BAY86-5283, MS-325) is indicated for Contrast agent for MRI scans.

Who makes Vasovist (BAY86-5283, MS-325)?

Vasovist (BAY86-5283, MS-325) is developed by Bayer (see full Bayer pipeline at /company/bayer).

What drug class is Vasovist (BAY86-5283, MS-325) in?

Vasovist (BAY86-5283, MS-325) belongs to the Contrast agent class. See all Contrast agent drugs at /class/contrast-agent.

What development phase is Vasovist (BAY86-5283, MS-325) in?

Vasovist (BAY86-5283, MS-325) is in Phase 3.

What are the side effects of Vasovist (BAY86-5283, MS-325)?

Common side effects of Vasovist (BAY86-5283, MS-325) include Nausea, Headache, Allergic reactions.

Drug class: All Contrast agent drugs
Manufacturer: Bayer — full pipeline
Therapeutic area: All drugs in Imaging
Indication: Drugs for Contrast agent for MRI scans
Compare: Vasovist (BAY86-5283, MS-325) vs similar drugs
Pricing: Vasovist (BAY86-5283, MS-325) cost, discount & access